title: Practice points - Neonatal Intensive Care Drug Manual
text: |
  Neonatal Intensive Care Drug Manual
  |
  bet | 238/654 | Sana | 03.01.2022 | Hajmi | 1,5 Mb. | | #14803 |
  Practice points
  |
  Central line is preferred as medication has high pH and can cause tissue irritation. Peripheral cannula may be used for short-term treatment but the IV site should be monitored carefully.
  |
  References
  |
  Kimberlin DW, Lin CY, Sanchez PJ, Demmler GJ, Dankner W, Shelton M, Jacobs RF, Vaudry W, Pass RF, Kiell JM, Soong SJ, Whitley RJ. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: A randomized, controlled trial. Journal of Pediatrics. 2003;143:16-25.
  Oliver SE, Cloud GA, Sanchez PJ, Demmler GJ, Dankner W, Shelton M, Jacobs RF, Vaudry W, Pass RF, Soong Sj, Whitley RJ, Kimberlin DW. Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving the central nervous system. Journal of Clinical Virology. 2009;46:S22-S6.
  Rawlinson WD, Boppana SB, Fowler KB, Kimberlin DW, Lazzarotto T, Alain S, Daly K, Doutre S, Gibson L, Giles ML, Greenlee J, Hamilton ST, Harrison GJ, Hui L, Jones CA, Palasanthiran P, Schleiss MR, Shand AW, van Zuylen WJ. Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy. The Lancet Infectious Diseases. 2017;17:e177-e88.
  Trang JM, Kidd L, Gruber W, Storch G, Demmler G, Jacobs R, Dankner W, Starr S, Pass R, Stagno S, Alford C, Soong SJ, Whitley RJ, Sommadossi JP. Linear single-dose pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. Clinical Pharmacology and Therapeutics. 1993;53:15-21.
  Kimberlin DW, Acosta EP, Sanchez PJ, Sood S, Agrawal V, Homans J, Jacobs RF, Lang D, Romero JR, Griffin J, Cloud GA, Lakeman FD, Whitley RJ, National Institute of A, Infectious Diseases Collaborative Antiviral Study G. Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease. J Infect Dis. 2008;197:836-45.
  SHPA, Ganciclovir monograph, Australian Injectable Handbook 7th Ed, 2017
  Roche, Valcyte monograph, MIMs, 2017
  Roche, Cymevene monograph, MIMs, 2017
  Trissel's 2 Clinical Pharmaceutics Database (Parenteral Compatibility), Ganciclovir monograph, accessed via Micromedex, 26/07/2017.
  El-Sayed MF, Goldfarb DM, Fulford M, Pernica JM. Severe late-onset multisystem cytomegalovirus infection in a premature neonate previously treated for congenital infection. BMC Pediatr. 2013;13:142.
  Fischer C, Meylan P, Bickle Graz M, Gudinchet F, Vaudaux B, Berger C, Roth-Kleiner M. Severe postnatally acquired cytomegalovirus infection presenting with colitis, pneumonitis and sepsis-like syndrome in an extremely low birthweight infant. Neonatology. 2010;97:339-45.
  Mehler K, Oberthuer A, Lang-Roth R, Kribs A. High rate of symptomatic cytomegalovirus infection in extremely low gestational age preterm infants of 22-24 weeks' gestation after transmission via breast milk. Neonatology. 2014;105:27-32.
  Muller A, Eis-Hubinger AM, Brandhorst G, Heep A, Bartmann P, Franz AR. Oral valganciclovir for symptomatic congenital cytomegalovirus infection in an extremely low birth weight infant. J Perinatol. 2008;28:74-6.
  Okulu E, Akin IM, Atasay B, Ciftci E, Arsan S, Turmen T. Severe postnatal cytomegalovirus infection with multisystem involvement in an extremely low birth weight infant. J Perinatol. 2012;32:72-4.
  |
  Original version Date: 18/09/2017
  |
  Author: Xiao
  |
  Current Version number: 1.0
  |
  Current Version Date: 10/12/2020
  |
  Risk Rating: Low
  |
  Due for Review: 10/12/2025
  |
  Approval by: DTC
  |
  Approval Date: TBA
  |
  |
  | |